CS
ALXN

Credit Suisse’s Alexion Pharmaceuticals ALXN Stock Holding History

Credit Suisse’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,744,843
Closed -$321M – 4675
2021
Q2 		$321M Buy
1,744,843
+373,222
+27% +$64.1M 0.17% 98
2021
Q1 		$210M Sell
1,371,621
-378,840
-22% -$58.6M 0.11% 198
2020
Q4 		$273M Sell
1,750,461
-211,695
-11% -$27.2M 0.13% 141
2020
Q3 		$225M Sell
1,962,156
-148,259
-7% -$16M 0.14% 141
2020
Q2 		$237M Sell
2,110,415
-1,064,144
-34% -$113M 0.17% 108
2020
Q1 		$285M Buy
3,174,559
+416,206
+15% +$40.8M 0.25% 70
2019
Q4 		$298M Buy
2,758,353
+763,163
+38% +$81.6M 0.22% 73
2019
Q3 		$195M Buy
1,995,190
+1,632,827
+451% +$184M 0.16% 107
2019
Q2 		$47.5M Sell
362,363
-14,180
-4% -$1.83M 0.04% 464
2019
Q1 		$50.9M Buy
376,543
+22,666
+6% +$2.82M 0.05% 417
2018
Q4 		$34.5M Sell
353,877
-4,778
-1% -$565K 0.04% 521
2018
Q3 		$49.9M Buy
358,655
+77,003
+27% +$9.66M 0.04% 424
2018
Q2 		$35M Sell
281,652
-44,809
-14% -$5.24M 0.03% 540
2018
Q1 		$36.4M Sell
326,461
-62,508
-16% -$7.47M 0.03% 563
2017
Q4 		$46.5M Sell
388,969
-30,170
-7% -$3.67M 0.04% 451
2017
Q3 		$58.8M Sell
419,139
-89,599
-18% -$12.2M 0.06% 368
2017
Q2 		$61.9M Sell
508,738
-60,228
-11% -$7.01M 0.06% 326
2017
Q1 		$69M Buy
568,966
+86,141
+18% +$11.1M 0.06% 325
2016
Q4 		$59.1M Sell
482,825
-113,742
-19% -$13.9M 0.06% 344
2016
Q3 		$73.1M Buy
596,567
+17,715
+3% +$2.28M 0.07% 287
2016
Q2 		$67.6M Buy
578,852
+37,492
+7% +$5.32M 0.07% 256
2016
Q1 		$75.4M Buy
541,360
+18,558
+4% +$2.72M 0.09% 227
2015
Q4 		$99.7M Buy
522,802
+34,833
+7% +$6.08M 0.11% 179
2015
Q3 		$76.3M Sell
487,969
-147,862
-23% -$27M 0.09% 230
2015
Q2 		$115M Buy
635,831
+87,081
+16% +$15M 0.11% 189
2015
Q1 		$95.1M Sell
548,750
-29,610
-5% -$5.36M 0.1% 220
2014
Q4 		$107M Buy
578,360
+33,640
+6% +$6.23M 0.1% 207
2014
Q3 		$90.3M Buy
544,720
+76,687
+16% +$12.6M 0.07% 265
2014
Q2 		$73.1M Sell
468,033
-22,786
-5% -$3.6M 0.06% 337
2014
Q1 		$74.7M Sell
490,819
-73,999
-13% -$11.8M 0.07% 271
2013
Q4 		$75.1M Buy
564,818
+97,377
+21% +$11.7M 0.07% 274
2013
Q3 		$54.3M Sell
467,441
-125,846
-21% -$13.8M 0.05% 325
2013
Q2 		$54.7M Buy
+593,287
New +$57.2M 0.06% 344

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Credit Suisse's ALXN Position: Q3 2021 in Review

Credit Suisse sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,744,843 shares — an estimated $321M sold.

Credit Suisse first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $321M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Credit Suisse reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Credit Suisse sold 1,744,843 Alexion Pharmaceuticals shares in Q3 2021, an estimated $321M.
  • Credit Suisse first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Credit Suisse's Alexion Pharmaceuticals position peaked at $321M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Credit Suisse's 13F filing for Q3 2021, filed 12 Nov 2021.